Please assess the completion status of the following clinical trial:

Trial Title: Otrivine: Quality of Life (QoL) Impact in a Real-World Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant's provision of a signed and dated electronic informed consent (eIC) form indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.~* Participant reporting a nasal congestion, and at least another common cold symptom among runny nose, sore throat, cough.~* Participant reporting a minimum score of 5 (moderate) for plugged nose associated with common cold symptoms and at least one other symptom of common cold (at least mild score of 3) as per the WURSS-21 questionnaire at screening.~* Participant reporting initiation of cold symptoms within no longer than 24 hours of prior to initiation of screening.~* Participants confirm common cold symptoms within 24 hours of study product receipt of minimum score of 5 (moderate) for plugged nose associated with common cold symptoms and at least one other symptom of common cold (at least mild score of 3) as per the WURSS-21 questionnaire.~* Male and female Participants.~* Participant that owns a smart device and willing to download the study app.~* Participant who is willing and able to complete all activities as shown in the Schedule of Activities independently on own smart devices.~* Participant is in good general and mental health.~* Participant who has a self-reported medical diagnosis of cardiovascular disease (including those with long QT syndrome), hyperthyroidism or diabetes mellitus, may be included if deemed acceptable by a medically qualified investigator.~* Participant who is showing a strong reaction to adrenergic substances, as manifested by signs of insomnia, dizziness, tremor, cardiac arrhythmias, or elevated blood pressure, may be included if deemed acceptable by a medically qualified investigator.~Exclusion Criteria:~* Participants under 18 years of age.~* Participants who are allergic to xylometazoline hydrochloride or any of the other ingredients in the spray (see product label).~* Participants who have had recent neurosurgery.~* Participants who self-report narrow angle glaucoma, chronic nasal inflammation with very dry nasal passages (rhinitis sicca or atrophic rhinitis), or enlarged prostate gland.~* Participants who self-report a rare tumor of the adrenal gland that produces high amounts of adrenaline and noradrenaline (phaeochromocytoma).~* Participants who are taking monoamine oxidase inhibitors (MAOIs) or have stopped taking them in the last 14 days.~* Participants who are pregnant, lactating, or plan to be pregnant or lactating during the course of the study.~* Participant who is currently using or has used a nasal decongestant (for example, adrenergic, steroids) within the last 7 days (or for more than 7 days) prior to initiating study treatment.~* Participants who have tested positive for COVID-19 within one month prior to enrollment into the study.~* Participants who have taken a vaccine one week prior to enrollment into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Otrivine Congestion Relief (Type: EXPERIMENTAL): Participants will be instructed to use the product per label and leaflet instructions: 1 spray in each nostril up to 3 times per day until resolution of symptoms or up to a maximum of 7 days, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).